AnalystsAdam WalshAdam Walsh's Stock Forecasts
AnalystsAdam Walsh
Sectors:
Industries:
Analyst Ranking
Top 31%
#1609 out of 5256 analysts
Average Return
+15.12%
Win Rate
50%7 out of 14
Risk vs Reward
Poor
Good
Adam Walsh's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Apellis Pharmaceuticals IncAPLS | +116.16% | $18.94 | $40.94 | 2026-03-12 - 2026-04-20 | Strong Buy |
Ascendis Pharma AASND | +58.48% | $70.69 | $112.03 | 2018-08-29 - 2019-08-30 | Strong Buy |
Galapagos NvGLPG | +39.87% | $92.18 | $128.93 | 2018-06-28 - 2019-06-28 | Strong Buy |
Galapagos NvGLPG | +33.71% | $119.71 | $160.07 | 2018-09-11 - 2019-09-12 | Strong Buy |
Ultragenyx Pharmaceutical IncRARE | +17.34% | $54.91 | $64.43 | 2018-04-17 - 2019-04-18 | Strong Buy |
Adam Walsh Analyst Color
Get additional color on Adam Walsh's coverage of popular stocks
Adam Walsh's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Equillium IncEQ | 2 | Strong Buy | $12.00 | +497.01% | Reiterates | 4 days ago |
Insmed IncINSM | 2 | Strong Buy | $212.00 | +48.44% | Reiterates | 4 days ago |
Apellis Pharmaceuticals IncAPLS | 1 | Strong Buy | $31.00 | -24.28% | Initiates Coverage On | a month ago |
Vtv Therapeutics IncVTVT | 1 | Strong Buy | $58.00 | +53.64% | Initiates Coverage On | 3 months ago |
Ascendis Pharma AASND | 2 | Strong Buy | $171.00 | N/A | Maintains | 6 years ago |
Reata Pharmaceuticals IncRETA | 2 | Strong Buy | $315.00 | N/A | Maintains | 6 years ago |
Galapagos NvGLPG | 2 | Strong Buy | $111.00 | N/A | Maintains | 8 years ago |
Corcept Therapeutics IncCORT | 2 | Hold | N/A | N/A | Downgrades | 8 years ago |
Ultragenyx Pharmaceutical IncRARE | 1 | Strong Buy | $77.00 | N/A | Maintains | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.